Prologue: Challenges and objectives for a crisis like no other
The background need-to-knows: An initially spiralling situation
In Q1 2021, the stakes had never been higher for AstraZeneca (AZ) in Asia-Pacific. Low- and middle- income countries, and developed nations too, were being battered by the catastrophic impact of COVID-19, with a devastating number of lives lost, health systems on the brink of collapse, and economies on their knees.
AZ had part of the solution to limit the damage being done by the virus: an effective vaccine that was manufactured in the region, which was also easily transported, stored, and administered,...